title: Bisdemethoxycurcumin inhibits ovarian cancer via reducing oxidative stress mediated MMPs expressions.
abstract: As one main active compound of curcuminoids, Bisdemethoxycurcumin (BDMC) possesses several biological activities, such as anti-inflammation and anti-cancer activities. However, the detailed mechanism of BDMC's anti-metastasis activity in ovarian cancer has not been clearly elucidated yet. In the present study, cell proliferation, wound healing motility, cell adhesion and invasion with or without BDMC were determined. In addition, western blot was used to examine proteins expressions. The lucigenin-enhanced luminescence was introduced to assess cellular oxidative stress. The luciferase reporter gene assay was introduced to evaluate the transcriptional activity of NF-κB. Finally, BDMC significantly inhibited the adhesion, migration, invasion and metastasis of SKOV-3 cells. Moreover, BDMC inhibited expressions of several degradation-associated proteins, such as matrix metalloproteinase-2 (MMP-2), matrix metalloproteinase-9 (MMP-9), CD147, urokinase plasminogen activator (uPA), intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), whereas increased expression of tissue inhibitor of metalloproteinase-1 (TIMP-1), in a dose-dependent manner. In addition, BDMC reduced generation of cellular superoxide in a dose-dependent manner. Furthermore, BDMC inhibited the phosphorylation levels of NF-κB p65 and IκB-α, and consequently reduced NF-κB-driven luciferase expression. Collectively, BDMC serves as a therapeutic medicine to suppress ovarian cancer, perhaps via inhibiting cellular oxidative stress and subsequently inactivating NF-κB pathway.
authors.affiliation: Department of Cardiology, Chengdu Military General Hospital, Chengdu 610083, China.
authors.forename: Haifeng
authors.initials: H
authors.lastname: Pei
authors.affiliation: Department of Cardiology, Chengdu Military General Hospital, Chengdu 610083, China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Orthopedics, Chengdu Military General Hospital, Chengdu 610083, China.
authors.forename: Lin
authors.initials: L
authors.lastname: Cui
authors.affiliation: Department of Cardiology, Chengdu Military General Hospital, Chengdu 610083, China.
authors.forename: Jiong
authors.initials: J
authors.lastname: Yang
authors.affiliation: Department of Cardiology, Chengdu Military General Hospital, Chengdu 610083, China.
authors.forename: Xiuchuan
authors.initials: X
authors.lastname: Li
authors.affiliation: Department of Cardiology, Chengdu Military General Hospital, Chengdu 610083, China.
authors.forename: Yongjian
authors.initials: Y
authors.lastname: Yang
authors.affiliation: Department of Obstetrics and Gynecology, Affiliated Guangren Hospital, College of Medicine, Xi'an Jiaotong University, Xi'an 710004, China.
authors.forename: Haixia
authors.initials: H
authors.lastname: Duan
mesh_terms: D000818:Animals; D002453:Cell Cycle / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D003474:Curcumin / Q000031:analogs & derivatives* / Q000494:pharmacology; D036381:Diarylheptanoids; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D020782:Matrix Metalloproteinases / Q000378:metabolism*; D051379:Mice; D041681:NIH 3T3 Cells; D010051:Ovarian Neoplasms / Q000378:metabolism / Q000473:pathology; D018384:Oxidative Stress / Q000187:drug effects*; D013997:Time Factors
chemical_list: D036381:Diarylheptanoids; C034786:bisdemethoxycurcumin; D020782:Matrix Metalloproteinases; D003474:Curcumin